|
Name |
Valylvaline anhydride
|
Molecular Formula | C10H18N2O2 | |
IUPAC Name* |
3,6-di(propan-2-yl)piperazine-2,5-dione
|
|
SMILES |
CC(C)C1C(=O)NC(C(=O)N1)C(C)C
|
|
InChI |
InChI=1S/C10H18N2O2/c1-5(2)7-9(13)12-8(6(3)4)10(14)11-7/h5-8H,1-4H3,(H,11,14)(H,12,13)
|
|
InChIKey |
QGMAWEIDGADSAC-UHFFFAOYSA-N
|
|
Synonyms |
Valylvaline anhydride; 5625-44-5; 3,6-di(propan-2-yl)piperazine-2,5-dione; 3,6-Diisopropyl-2,5-piperazinedione; Cyclo(L-Val-L-Val); L-Valyl-valine anhydride; 2,5-Piperazinedione, 3,6-bis(1-methylethyl)-; SCHEMBL6439632; DTXSID00971680; 3,6-Diisopropylpiperazin-2,5-dione; 3,6-diisopropylpiperazine-2,5-dione; AKOS006281827; 3,6-diisopropylpipera-zine-2,5-dione; 3,6-Diisopropyl-2,5-piperazinedione #; (l,l)-cis-3,6-Diisopropylpiperazine-2,5-dione; 3,6-Di(propan-2-yl)-3,6-dihydropyrazine-2,5-diol; 2,5 Piperazinedione, 3,6-bis(1-methylethyl)-, (35)-trans-
|
|
CAS | 5625-44-5 | |
PubChem CID | 519728 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 198.26 | ALogp: | 1.4 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 58.2 | Aromatic Rings: | 1 |
Heavy Atoms: | 14 | QED Weighted: | 0.685 |
Caco-2 Permeability: | -4.856 | MDCK Permeability: | 0.00000673 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.37 |
Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.082 |
30% Bioavailability (F30%): | 0.063 |
Blood-Brain-Barrier Penetration (BBB): | 0.932 | Plasma Protein Binding (PPB): | 41.67% |
Volume Distribution (VD): | 0.786 | Fu: | 52.72% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.084 |
CYP2C19-inhibitor: | 0.037 | CYP2C19-substrate: | 0.714 |
CYP2C9-inhibitor: | 0.026 | CYP2C9-substrate: | 0.087 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.128 |
CYP3A4-inhibitor: | 0.045 | CYP3A4-substrate: | 0.268 |
Clearance (CL): | 4.907 | Half-life (T1/2): | 0.728 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.308 |
Drug-inuced Liver Injury (DILI): | 0.24 | AMES Toxicity: | 0.04 |
Rat Oral Acute Toxicity: | 0.155 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.039 | Carcinogencity: | 0.035 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.018 |
Respiratory Toxicity: | 0.092 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000904 | 0.634 | D0L7LC | 0.314 | ||||
ENC000990 | 0.444 | D0R6BR | 0.219 | ||||
ENC002212 | 0.444 | D0B2OT | 0.212 | ||||
ENC002255 | 0.410 | D05TMQ | 0.210 | ||||
ENC002257 | 0.400 | D0A4JK | 0.210 | ||||
ENC002604 | 0.397 | D0A3HB | 0.207 | ||||
ENC005246 | 0.397 | D01HNL | 0.204 | ||||
ENC001901 | 0.370 | D00MYT | 0.200 | ||||
ENC005409 | 0.370 | D0F0YZ | 0.200 | ||||
ENC005973 | 0.370 | D05BQK | 0.200 |